bluuebunny/crossref_metadata_2025_split huggingface dataset:
Agreement of implantable collamer lens sizes using parameters from different devices
Authors: Nonpassopon Manachai , Jongkhajornpong Passara , Phimpho Prae , Cheewaruangroj Nontawat , Lekhanont Kaevalin , Chuckpaiwong Varintorn 
Published: March 2022

ObjectiveTo assess agreement and repeatability of white-to-white (WTW) and anterior chamber depth (ACD), and agreement of implantable collamer lens (ICL) size using these measurements from different devices.Methods and analysisA retrospective review of 83 eyes with ICL implantation (42 patients) was conducted. The agreement of WTW (measured with WaveLight Topolyzer and Orbscan IIz) and ACD (measured with WaveLight Oculyzer and Orbscan IIz) was analysed. Correlation of ICL sizes and difference of eyes with unacceptable vaults between two data sets (WaveLight platform; Topolyzer and Oculyzer and Orbscan IIz) were assessed.ResultsAverage WTW measured by Orbscan IIz and Topolyzer demonstrated good agreement (Ρ 0.884) with low systematic bias (−0.03±0.1 mm) and narrow 95% limits of agreement (LoA) of −0.28 to 0.22. Average ACD measured by Orbscan IIz and Oculyzer also showed good agreement (Ρ 0.903) with low systematic bias (−0.04±0.1 mm) and relatively narrow 95% LoA (0.2 to 0.12). ICL size selected according to two data sets showed moderate to strong level of agreement (Kappa=0.81). There was a statistically significant difference (p<0.001) in the proportion of eyes with unacceptable postoperative vaults when using the Wavelight platform data set (five eyes, 6.02%) and the Orbscan IIz data set (12 eyes, 14.46%).ConclusionAlthough the agreement of WTW and ACD between devices was good, there was a significant difference in proportion of eyes with unacceptable postoperative vaults when using two data sets. Therefore, Topolyzer and Oculyzer might not be suitable for operating interchangeably with Orbscan IIz for ICL size selection.
Population-based study of influenza and invasive meningococcal disease among Greek children during the COVID-19 pandemic
Authors: Ktena Danai , Kourkouni Eleni , Kontopidou Flora , Gkolfinopoulou Kassiani , Papadima Kalliopi , Georgakopoulou Theano , Magaziotou Ioanna , Andreopoulou Anastasia , Tzanakaki Georgina , Zaoutis Theoklis , Papaevangelou Vassiliki 
Published: March 2022

BackgroundAiming to the containment of the coronavirus disease 2019 (COVID-19) pandemic, governments worldwide have implemented a series of non-pharmaceutical interventions. Many of them and especially school closures have impacted the circulation of multiple airborne pathogens among children and adolescents. This study investigates the incidence of influenza and invasive meningococcal disease among children aged 0–14 years in Greece during the COVID-19 pandemic.MethodsData regarding the number of influenza-like illness cases, influenza-related paediatric intensive care unit (PICU) admissions and invasive meningococcal disease cases among children 0–14 years old were obtained from the National Public Health Organization. The incidence of the two diseases during the COVID-19 pandemic period (2020/2021) was compared with that of the six preceding seasons (2014–2019).ResultsA notable decrease was observed in both influenza and invasive meningococcal disease cases during the period 2020/2021 compared with the years 2014–2019. The mean annual rate of influenza-like illness cases and influenza-related PICU admissions in children 0–14 years old has reduced by 66.9% and 100%, respectively, while the mean annual invasive meningococcal disease rate has declined by 70%. Both weekly influenza-like illness and monthly invasive meningococcal disease rates were significantly decreased.ConclusionsThe activity of influenza and invasive meningococcal disease in the children and adolescents of Greece has decreased during the COVID-19 pandemic period. Reduced transmission is likely related to the public health measures that were implemented to control the pandemic. The value of these measures may have relevance to the future management of influenza or invasive meningococcal disease epidemics.
Effects of tall man lettering on the visual behaviour of critical care nurses while identifying syringe drug labels: a randomised in situ simulation
Authors: Lohmeyer Quentin , Schiess Cornel , Wendel Garcia Pedro David , Petry Heidi , Strauch Eric , Dietsche Andreas , Schuepbach Reto A. , Buehler Philipp K. , Hofmaenner Daniel A. 
Published: March 2022

BackgroundPatients in intensive care units are prone to the occurrence of medication errors. Look-alike, sound-alike drugs with similar drug names can lead to medication errors and therefore endanger patient safety. Capitalisation of distinct text parts in drug names might facilitate differentiation of medication labels. The aim of this study was to test whether the use of such ‘tall man’ lettering (TML) reduces the error rate and to examine effects on the visual attention of critical care nurses while identifying syringe labels.MethodsThis was a prospective, randomised in situ simulation conducted at the University Hospital Zurich, Zurich, Switzerland. Under observation by eye tracking, 30 nurses were given 10 successive tasks involving the presentation of a drug name and its selection from a dedicated set of 10 labelled syringes that included look-alike and sound-alike drug names, half of which had TML-coded labels.Error rate as well as dwell time, fixation count, fixation duration and revisits were analysed using a linear mixed-effects model analysis to compare TML-coded with non-TML-coded labels.ResultsTML coding of syringe labels led to a significant decrease in the error rate (from 5.3% (8 of 150 in non-TML-coded sets) to 0.7% (1 of 150 in TML-coded sets), p<0.05). Eye tracking further showed that TML affects visual attention, resulting in longer dwell time (p<0.01), more and longer fixations (p<0.05 and p<0.01, respectively) on the drug name as well as more frequent revisits (p<0.01) compared with non-TML-coded labels. Detailed analysis revealed that these effects were stronger for labels using TML in the mid-to-end position of the drug name.ConclusionsTML in drug names changes visual attention while identifying syringe labels and supports critical care nurses in preventing medication errors.
Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus
Authors: Hasse Stephan , Julien Anne-Sophie , Duchez Anne-Claire , Zhao Chenqi , Boilard Eric , Fortin Paul R , Bourgoin Sylvain G 
Published: March 2022

BackgroundExtracellular vesicles (EVs) released by blood cells have proinflammation and procoagulant action. Patients with systemic lupus erythematosus (SLE) present high vascular inflammation and are prone to develop cardiovascular diseases. Therefore, we postulated that the EV populations found in blood, including platelet EVs (PEVs) and red blood cell EVs (REVs), are associated with SLE disease activity and SLE-associated cardiovascular accidents.MethodWe assessed autotaxin (ATX) plasma levels by ELISA, the platelet activation markers PAC1 and CD62P, ATX bound to platelets and the amounts of plasma PEVs and REVs by flow cytometry in a cohort of 102 patients with SLE, including 29 incident cases of SLE and 30 controls. Correlation analyses explored the associations with the clinical parameters.ResultPlatelet activation markers were increased in patients with SLE compared with healthy control, with the marker CD62P associated with the SLE disease activity index (SLEDAI). The incident cases show additional associations between platelet markers (CD62P/ATX and PAC1/CD62P) and the SLEDAI. Compared with controls, patients with SLE presented higher levels of PEVs, phosphatidylserine positive (PS+) PEVs, REVs and PS+REVs, but there is no association with disease activity. When stratified according to the plasma level of PS+REVs, the group of patients with SLE with a high level of PS+REVs presented a higher number of past thrombosis events and higher ATX levels.ConclusionIncident and prevalent forms of SLE cases present similar levels of platelet activation markers, with CD62P correlating with disease activity. Though EVs are not associated with disease activity, the incidence of past thrombotic events is higher in patients with a high level of PS+REVs.
Predictors of dysphagia screening and pneumonia among patients with acute ischaemic stroke in China: findings from the Chinese Stroke Center Alliance (CSCA)
Authors: Liang Jianshu , Yin Zhike , Li Zixiao , Gu Hongqiu , Yang Kaixuan , Xiong Yunyun , Wang Yongjun , Wang Chunjuan 
Published: March 2022

Background and purposeGuidelines recommend dysphagia screening to identify those at high risk of pneumonia. However, little is known about the prevalence and predictors of dysphagia screening and pneumonia among patients with acute ischaemic stroke in China.MethodsUsing data from the Chinese Stroke Center Alliance, which is a multicentre, prospective, consecutive patient enrolment programme, univariate and multivariate analyses were conducted to identify patient and hospital characteristics associated with dysphagia screening and pneumonia during acute hospitalisation.ResultsOf 790 811 patients admitted to 1476 hospitals, 622 718 (78.7%) underwent dysphagia screening, and 64 398 (8.1%) developed pneumonia. Patients in stroke units were more likely to be screened for dysphagia than those not in stroke units (OR 1.50; 95% CI 1.48 to 1.52), while patients with a past history of stroke were less likely to be screened (OR 0.87; 95% CI 0.86 to 0.88). Dysphagia screening (OR 1.46; 95% CI 1.30 to 1.65), dysphagia (OR 7.31; 95% CI 7.15 to 7.46), and admission to stroke units (OR 1.17; 95% CI 1.14 to 1.19) were significantly associated with a greater risk of pneumonia.ConclusionsDysphagia was a critical factor in the development of pneumonia. Nearly one in five patients with acute ischaemic stroke in the Chinese Stroke Center Alliance were not screened for dysphagia. Pneumonia prevention during acute hospitalisation is dependent not only on dysphagia screening but also on the effectiveness of subsequent dysphagia management interventions. Further studies are needed to elucidate the relationship between dysphagia screening, stroke unit care and pneumonia in patients with acute ischaemic stroke.
A comparison between acute large vessel occlusion in the posterior circulation and anterior circulation after endovascular treatment: the ANGEL-ACT registry experience
Authors: Sun Xuan , Zhang Jingyu , Tong Xu , Jia Baixue , Mo Dapeng , Ma Ning , Gao Feng , Liu Lian , Huo Xiaochuan , Song Ligang , Deng Yiming , Miao Zhongrong 
Published: March 2022

Background and purposeEndovascular treatment (EVT) has shown an overwhelming benefit for acute anterior circulation artery occlusion (ACO). Whether it can achieve the same outcomes in posterior circulation artery occlusion (PCO) has not been well explained. We aimed to evaluate the characteristics and prognosis of ACO and PCO after EVT in a nationwide registry.MethodThe present analysis was based on the prospective ANGEL-ACT Registry in China between November 2017 and March 2019. Demographic data, periprocedural times, recanalisation rate, intracranial haemorrhage (ICH) and 90-day functional outcomes were compared between the ACO and PCO groups.ResultsA total of 1793 patients were analysed including 397 (22.1%) consecutive patients with PCO and 1396 (77.9%) patients with ACO treated with EVT. A larger proportion of patients with PCO had intracranial atherosclerotic disease and received extra angioplasty during EVT. Successful recanalisation and 90-day favourable functional outcomes did not differ significantly between the two groups. Patients with PCO showed lower 24-hour ICH and symptomatic ICH rates. There was a trend towards higher mortality rate in the PCO group (22.09% vs 14.44%; adjusted OR 1.286 (95% CI 0.820 to 2.017), p=0.2731), especially when the onset to puncture time was over 6 hours (30.77% vs 11.13%; adjusted OR 2.673 (95% CI 1.280 to 5.583), p=0.0089, interactive p=0.0002).ConclusionsIn this large prospective multicentre registry, there was a significant difference in the characteristics and periprocedural features between patients with PCO and ACO. However, successful recanalisation and 90-day favourable functional outcomes in PCO were equivalent to those in ACO.
Inflammatory biomarkers and cerebral small vessel disease: a community-based cohort study
Authors: Zhang Ding-Ding , Cao Yuan , Mu Jing-Yu , Liu Yi-Ming , Gao Feng , Han Fei , Zhai Fei-Fei , Zhou Li-Xin , Ni Jun , Yao Ming , Li Ming-Li , Jin Zheng-Yu , Zhang Shu-Yang , Cui Li-Ying , Shen Yong , Zhu Yi-Cheng 
Published: March 2022

Background and purposeAlthough inflammation has been proposed to be a candidate risk factor for cerebral small vessel disease (CSVD), previous findings remain largely inconclusive and vary according to disease status and study designs. The present study aimed to investigate possible associations between inflammatory biomarkers and MRI markers of CSVD.MethodsA group of 15 serum inflammatory biomarkers representing a variety of those putatively involved in the inflammatory cascade was grouped and assessed in a cross-sectional study involving 960 stroke-free subjects. The biomarker panel was grouped as follows: systemic inflammation (high-sensitivity C reactive protein (hsCRP), interleukin 6 and tumour necrosis factor α), endothelial-related inflammation (E-selectin, P-selectin, intercellular adhesion molecule 1, vascular cell adhesion molecule 1 (VCAM-1), CD40 ligand, lipoprotein-associated phospholipase A2, chitinase-3-like-1 protein and total homocysteine (tHCY)) and media-related inflammation (matrix metalloproteinases 2, 3 and 9, and osteopontin). The association(s) between different inflammatory groups and white matter hyperintensity (WMH), lacunes, cerebral microbleeds (CMBs), enlarged perivascular space (PVS) and the number of deep medullary veins (DMVs) were investigated.ResultsHigh levels of serum endothelial-related inflammatory biomarkers were associated with both increased WMH volume (R2=0.435, p=0.015) and the presence of lacunes (R2=0.254, p=0.027). Backward stepwise elimination of individual inflammatory biomarkers for endothelial-related biomarkers revealed that VCAM-1 was significant for WMH (β=0.063, p=0.005) and tHCY was significant for lacunes (β=0.069, p<0.001). There was no association between any group of inflammatory biomarkers and CMBs or PVS. Systemic inflammatory biomarkers were associated with fewer DMVs (R2=0.032, p=0.006), and backward stepwise elimination of individual systemic-related inflammatory biomarkers revealed that hsCRP (β=−0.162, p=0.007) was significant.ConclusionWMH and lacunes were associated with endothelial-related inflammatory biomarkers, and fewer DMVs were associated with systemic inflammation, thus suggesting different underlying inflammatory processes and mechanisms.
Treatment with ddAVP improves platelet-based coagulation in a rat model of traumatic hemorrhagic shock
Authors: Wirtz Mathijs R , Roelofs Joris J , Goslings J Carel , Juffermans Nicole P 
Published: March 2022

ObjectivesTrauma-induced hemorrhagic shock is characterized by increased endothelial permeability and coagulopathy. Vasopressin analog ddAVP (desmopressin) acts by reorganizing and redistributing adhesive and tight junction molecules, enhancing endothelial barrier function. Furthermore, ddAVP increases von Willebrand factor (vWF) plasma levels and thereby potentially enhances platelet-based coagulation. The objective of this study was to assess whether the use of ddAVP results in improvement of both endothelial barrier function and platelet-based coagulation, thereby improving shock reversal and reduce organ failure in a rat model of trauma and transfusion.MethodsBlood products were prepared from syngeneic rat blood according to blood bank standards. Polytrauma was induced in Sprague Dawley rats by a fractured femur and crush injury to the intestines and liver. The rats were hemorrhaged until a mean arterial pressure of 40 mm Hg and transfused with RBCs, fresh frozen plasmas and platelets in a 1:1:1 ratio, and randomized to receive a single dose of ddAVP (n=7 per group). Blood samples were taken up to 6 hours after trauma to assess biochemistry, markers of endothelial injury and coagulation status by rotational thromboelastometry (ROTEM). Organ damage was assessed by histopathology.ResultsRats receiving ddAVP showed significantly better shock reversal compared with controls. Also, coagulation parameters remained stable in the ddAVP treated group, whereas rats in the control group showed deterioration of coagulation parameters, including decreased clot strength and decreased platelet functioning (89% (IQR 82% to 92%) of baseline values). Platelet count and vWF antigen levels at exsanguination did not differ between groups. ddAVP did not reduce markers of endothelial dysfunction nor markers of organ injury.ConclusionsThe use of ddAVP in a rat trauma-transfusion model improved shock parameters and ROTEM parameters of clot formation. However, this did not abrogate the amount of organ failure.Level of evidenceLevel III.
Abstract BS1-1: PR
Authors: Hagan C 
Published: March 2022

Abstract
Much debate exists surrounding how progesterone receptor (PR) expression and activation by native progesterone affects hormone receptor (HR)-positive breast cancer cells. While its expression is conserved in the majority of HR+ breast cancers, studies have failed to identify a clear link between progesterone signaling and breast cancer proliferation, in contrast to what has been shown for ER signaling. Clinically, many studies have utilized PR expression as an indicator of ER signaling, with associations between PR expression demonstrating greater responsiveness to anti-estrogen therapies and outcomes. However, convincing clinical trial data have shown that women taking progestin (synthetic progesterone)-containing hormone replacement therapy (HRT) have a significantly increased risk of developing breast cancer. Likewise, other clinical studies have demonstrated that progestins contribute to the development of more invasive breast cancers and increase mortality. These clinical findings are supported by a variety of pre-clinical studies using animal models, which collectively suggest that PR signaling enhances the development of invasive breast cancer. Finally, our studies and those of others suggest that PR has a specific transcriptional impact that is distinct from ER signaling. Collectively, these studies have demonstrated a key role for PR in the progression and outcome of HR+ breast cancer, which is distinct from estrogen-mediated proliferation signaling. We believe the lack of clinically available PR-targeted therapies in breast cancer is due to a lack of knowledge about exactly how PR contributes to breast cancer progression, as studies have failed to define a conclusive role for PR signaling in tumor growth. However, our recent studies have unexpectedly revealed a significant immune modulatory role for PR. Specifically, our results have demonstrated a clear role for PR in suppressing local anti-tumor immunity, which may explain reduced T-cell infiltrates and responsiveness to immune checkpoint inhibition observed in HR+ breast cancer. This presentation will discuss the current controversial data regarding PR and progesterone in promoting breast cancer proliferation, as well as highlight new data suggesting that PR/progesterone promote immune shielding for developing breast cancers.
Citation Format: C Hagan. PR [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr BS1-1.
Abstract ES1-3: The ideal partner to HER2 directed therapies
Authors: Hurvitz S 
Published: March 2022

Abstract
Approximately ten percent of breast cancers are characterized by amplification/overexpression of HER2 with expression of one or both hormone receptors, deemed “double positive” or “triple positive” breast cancer. Though this cancer subtype has a lower chance of pathologic complete response with neoadjuvant therapy, it benefits as much from HER2-targeted therapies and has a long-term outcome that is as good or better than outcomes associated with the hormone receptor negative, HER2-positive subtype. Importantly, hormone receptor expression provides another opportunity to target additional signaling pathways implicated in tumor cell growth and survival, thus potentially expanding the armamentarium of effective therapeutics for this cancer subtype. In this presentation, clinical trial evidence evaluating the use of HER2-targeted agents plus endocrine therapy in the curative and advanced stage settings will be considered, including recent data directly comparing an endocrine-based versus chemotherapy-based approach. Results from studies evaluating whether the addition of endocrine therapy to chemotherapy plus HER2-directed treatment leads to antagonistic, null, or additive effects will be presented. The benefit of HER1/HER2-directed tyrosine kinase inhibitors such as lapatinib and neratinib based on tumor hormone receptor expression will be assessed. Finally, data from preclinical and clinical studies evaluating novel therapeutic strategies including the use of CDK4/6- or PI3K-pathway inhibitors will be considered and ongoing clinical trials addressing the optimal management of this disease subtype will be reviewed.
Citation Format: S Hurvitz. The ideal partner to HER2 directed therapies [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES1-3.
Abstract ES4-1: Acupuncture
Authors: Bao T 
Published: March 2022

Abstract
Acupuncture is a Traditional Chinese Medicine technique that involves inserting and manipulating filiform needles into specific points on the body to alleviate symptoms. Although its mechanisms are not fully established, acupuncture appears to interact with and modulate the functioning of nerves, neurotransmitters, and neurohormones. Acupuncture has been used as a complementary therapy to treat a wide range of conditions experienced by breast cancer survivors. In this education session, I will discuss the use of acupuncture to reduce breast cancer treatment-related toxicities such as chemotherapy-induced nausea, vomiting, peripheral neuropathy, and cognitive-impairment; insomnia; hot flashes; and aromatase inhibitor-associated arthralgias. I will start by discussing the definition and mechanisms of acupuncture. I will then share clinical evidence and ongoing trials supporting and investigating the use of acupuncture for these toxicities, and end with a summary of my recommendations.
Citation Format: T Bao. Acupuncture [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES4-1.